Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis
CONCLUSIONS: The meta-analysis showed that nirmatrelvir/ritonavir and sotrovimab have similar effectiveness in treating COVID-19 patients. However, the certainty of evidence supporting these findings is low. High-quality research is needed to better compare these interventions in COVID-19.PMID:38457124 | DOI:10.1080/14787210.2024.2326561 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - March 8, 2024 Category: Infectious Diseases Authors: Behnam Amani Bahman Amani Source Type: research
Nirmatrelvir-ritonavir use among adults hospitalized with COVID-19 during the Omicron phase of the COVID-19 pandemic, Canadian Nosocomial Infection Surveillance Program
CONCLUSION: These findings from a large sentinel network of Canadian acute-care hospitals suggest that nirmatrelvir-ritonavir is being used to treat adult COVID-19 patients at admission who are at risk of progression to severe disease or those who acquired COVID-19 in hospital. Additional research on the efficacy and indications for nirmatrelvir-ritonavir use in hospitalized patients is warranted to inform future policies and guidelines.PMID:38455882 | PMC:PMC10917417 | DOI:10.14745/ccdr.v49i78a07 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 8, 2024 Category: Infectious Diseases Authors: Robyn Mitchell Diane Lee Linda Pelude Jeannette Comeau John Conly Chelsey Ellis Jennifer Ellison John Embil Gerald Evans Lynn Johnston Jennie Johnstone Kevin Katz Pamela Kibsey Bonita Lee Marie-Astrid Lefebvre Yves Longtin Allison McGeer Dominik Mertz Jes Source Type: research
Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis
CONCLUSIONS: The meta-analysis showed that nirmatrelvir/ritonavir and sotrovimab have similar effectiveness in treating COVID-19 patients. However, the certainty of evidence supporting these findings is low. High-quality research is needed to better compare these interventions in COVID-19.PMID:38457124 | DOI:10.1080/14787210.2024.2326561 (Source: Expert Review of Anti-Infective Therapy)
Source: Expert Review of Anti-Infective Therapy - March 8, 2024 Category: Infectious Diseases Authors: Behnam Amani Bahman Amani Source Type: research
Nirmatrelvir and ritonavir
Clin Ther. 2024 Mar 7:S0149-2918(24)00042-0. doi: 10.1016/j.clinthera.2024.02.004. Online ahead of print.NO ABSTRACTPMID:38458901 | DOI:10.1016/j.clinthera.2024.02.004 (Source: Clinical Therapeutics)
Source: Clinical Therapeutics - March 8, 2024 Category: Drugs & Pharmacology Authors: Paul Beninger Source Type: research
Nirmatrelvir-ritonavir use among adults hospitalized with COVID-19 during the Omicron phase of the COVID-19 pandemic, Canadian Nosocomial Infection Surveillance Program
CONCLUSION: These findings from a large sentinel network of Canadian acute-care hospitals suggest that nirmatrelvir-ritonavir is being used to treat adult COVID-19 patients at admission who are at risk of progression to severe disease or those who acquired COVID-19 in hospital. Additional research on the efficacy and indications for nirmatrelvir-ritonavir use in hospitalized patients is warranted to inform future policies and guidelines.PMID:38455882 | PMC:PMC10917417 | DOI:10.14745/ccdr.v49i78a07 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 8, 2024 Category: Infectious Diseases Authors: Robyn Mitchell Diane Lee Linda Pelude Jeannette Comeau John Conly Chelsey Ellis Jennifer Ellison John Embil Gerald Evans Lynn Johnston Jennie Johnstone Kevin Katz Pamela Kibsey Bonita Lee Marie-Astrid Lefebvre Yves Longtin Allison McGeer Dominik Mertz Jes Source Type: research
Nirmatrelvir-ritonavir use among adults hospitalized with COVID-19 during the Omicron phase of the COVID-19 pandemic, Canadian Nosocomial Infection Surveillance Program
CONCLUSION: These findings from a large sentinel network of Canadian acute-care hospitals suggest that nirmatrelvir-ritonavir is being used to treat adult COVID-19 patients at admission who are at risk of progression to severe disease or those who acquired COVID-19 in hospital. Additional research on the efficacy and indications for nirmatrelvir-ritonavir use in hospitalized patients is warranted to inform future policies and guidelines.PMID:38455882 | PMC:PMC10917417 | DOI:10.14745/ccdr.v49i78a07 (Source: Can Commun Dis Rep)
Source: Can Commun Dis Rep - March 8, 2024 Category: Infectious Diseases Authors: Robyn Mitchell Diane Lee Linda Pelude Jeannette Comeau John Conly Chelsey Ellis Jennifer Ellison John Embil Gerald Evans Lynn Johnston Jennie Johnstone Kevin Katz Pamela Kibsey Bonita Lee Marie-Astrid Lefebvre Yves Longtin Allison McGeer Dominik Mertz Jes Source Type: research
Impact of loperamide on the pharmacokinetics and tissue disposition of ritonavir-boosted oral docetaxel therapy; a preclinical assessment
ConclusionThese results suggest that delayed loperamide administration can be added to ritonavir-boosted oral docetaxel treatment, without affecting the overall systemic exposure of docetaxel. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - March 8, 2024 Category: Cancer & Oncology Source Type: research
The Role of CYPs and Transporters in the Biotransformation and Transport of the Anti-hepatitis C Antiviral Agents Asunaprevir, Daclatasvir, and Beclabuvir: Impact of Liver Disease, Race and Drug-drug Interactions on Safety and Efficacy
This article reviews the biotransformation and disposition of these drugs in relation to the safety and efficacy of therapy. CYP3A4 and 3A5 catalyze the oxidative biotransformation of the drugs, while P-glycoprotein mediates their efflux from tissues. Asunaprevir is also a substrate for the influx transporters OATP1B1 and OATP2B1 and the efflux transporter MRP2, while beclabuvir is also a substrate for the efflux transporter BCRP. Liver disease decreases the expression of CYPs and transporters that mediate drug metabolism and disposition. Serum asunaprevir concentrations, but not those of daclatasvir or beclabuvir, are inc...
Source: Current Drug Metabolism - March 5, 2024 Category: Drugs & Pharmacology Authors: Michael Murray Source Type: research
The Role of CYPs and Transporters in the Biotransformation and Transport of the Anti-hepatitis C Antiviral Agents Asunaprevir, Daclatasvir, and Beclabuvir: Impact of Liver Disease, Race and Drug-drug Interactions on Safety and Efficacy
This article reviews the biotransformation and disposition of these drugs in relation to the safety and efficacy of therapy. CYP3A4 and 3A5 catalyze the oxidative biotransformation of the drugs, while P-glycoprotein mediates their efflux from tissues. Asunaprevir is also a substrate for the influx transporters OATP1B1 and OATP2B1 and the efflux transporter MRP2, while beclabuvir is also a substrate for the efflux transporter BCRP. Liver disease decreases the expression of CYPs and transporters that mediate drug metabolism and disposition. Serum asunaprevir concentrations, but not those of daclatasvir or beclabuvir, are inc...
Source: Current Drug Metabolism - March 5, 2024 Category: Drugs & Pharmacology Authors: Michael Murray Source Type: research
Cancers, Vol. 16, Pages 1055: Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients
Conclusions: In the treatment of mild-to-moderate COVID-19 in cancer patients, Molnupiravir was comparable to Nirmatrelvir/Ritonavir in preventing progression to severe disease/death and rebound events, and it had a superior safety profile. (Source: Cancers)
Source: Cancers - March 5, 2024 Category: Cancer & Oncology Authors: Andrea J. Haddad Ray Y. Hachem Mohamed Moussa Ying Jiang Hiba R. Dagher Patrick Chaftari Anne-Marie Chaftari Issam I. Raad Tags: Article Source Type: research
The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance
Antiviral Res. 2024 Mar 2:105840. doi: 10.1016/j.antiviral.2024.105840. Online ahead of print.ABSTRACTHost targeting antiviral drugs (HTA) are directed against cellular mechanisms which can be exploited by viruses. These mechanisms are essential for viral replication, because missing functions cannot be compensated by the virus. However, this assumption needs experimental proof. Here we compared the HTA Zapnometinib (ZMN), with direct acting antivirals (DAA) (Remdesivir (RDV), Molnupiravir (MPV), Nirmatrelvir (NTV), Ritonavir (RTV), Paxlovid PAX)), in terms of their potency to induce reduced drug susceptibilities in SARS-C...
Source: Antiviral Research - March 4, 2024 Category: Virology Authors: Andr é Schreiber Franziska Rodner Nicole Oberberg Darisuren Anhlan Stefan Bletz Alexander Mellmann Oliver Planz Stephan Ludwig Source Type: research
The host-targeted antiviral drug Zapnometinib exhibits a high barrier to the development of SARS-CoV-2 resistance
Antiviral Res. 2024 Mar 2:105840. doi: 10.1016/j.antiviral.2024.105840. Online ahead of print.ABSTRACTHost targeting antiviral drugs (HTA) are directed against cellular mechanisms which can be exploited by viruses. These mechanisms are essential for viral replication, because missing functions cannot be compensated by the virus. However, this assumption needs experimental proof. Here we compared the HTA Zapnometinib (ZMN), with direct acting antivirals (DAA) (Remdesivir (RDV), Molnupiravir (MPV), Nirmatrelvir (NTV), Ritonavir (RTV), Paxlovid PAX)), in terms of their potency to induce reduced drug susceptibilities in SARS-C...
Source: Antiviral Research - March 4, 2024 Category: Virology Authors: Andr é Schreiber Franziska Rodner Nicole Oberberg Darisuren Anhlan Stefan Bletz Alexander Mellmann Oliver Planz Stephan Ludwig Source Type: research
Discovery and development of COVID-19 vaccines and therapeutics: nonclinical perspectives
J Toxicol Sci. 2024;49(3):79-94. doi: 10.2131/jts.49.79.ABSTRACTThe development and regulatory review of BNT162b2, a COVID-19 vaccine, and PaxlovidTM (nirmatrelvir tablets/ritonavir tablets), a COVID-19 therapeutic, are benchmarks for accelerated innovation during a global pandemic. Rapid choice of the SARS-CoV-2 spike protein and main protease (Mpro) as targets for the vaccine and therapeutic, respectively, leveraged the available knowledge of the biology of SARS-CoV-2 and related viruses. The nonclinical immunogenicity and safety of BNT162b2 was rigorously assessed. Likewise, a comprehensive nonclinical safety assessment...
Source: Journal of Toxicological Sciences - March 3, 2024 Category: Toxicology Authors: Nasir Khan Jean Sathish Cynthia M Rohde Source Type: research
